{"id":"onabotulinumtoxina-24-u","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by blocking the release of acetylcholine, a neurotransmitter that signals muscle contraction. This results in a temporary reduction in muscle activity, which can help alleviate symptoms of conditions such as blepharospasm and cervical dystonia.","oneSentence":"onabotulinumtoxinA 24 U works by temporarily paralyzing muscles to treat muscle spasms and other conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:21.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06047457","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-09-29","conditions":"Episodic Migraine","enrollment":751},{"nctId":"NCT06047444","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2023-10-12","conditions":"Chronic Migraine","enrollment":759},{"nctId":"NCT07360483","phase":"NA","title":"Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-01-01","conditions":"Hypertrophic Scars","enrollment":48},{"nctId":"NCT05028569","phase":"PHASE3","title":"Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-11-05","conditions":"Episodic Migraine","enrollment":775},{"nctId":"NCT03848143","phase":"PHASE2","title":"Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain","status":"COMPLETED","sponsor":"Isabel Moreno Hay","startDate":"2019-09-11","conditions":"Neuropathic Pain","enrollment":10},{"nctId":"NCT05872932","phase":"PHASE2, PHASE3","title":"Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment","status":"COMPLETED","sponsor":"Sebahattin Celik MD","startDate":"2023-12-30","conditions":"Obesity","enrollment":131},{"nctId":"NCT04622254","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-11-12","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":368},{"nctId":"NCT04594213","phase":"PHASE3","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","status":"COMPLETED","sponsor":"Merz North America, Inc.","startDate":"2020-09-23","conditions":"Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)","enrollment":362},{"nctId":"NCT03712449","phase":"PHASE4","title":"A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-01-22","conditions":"Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality","enrollment":59},{"nctId":"NCT03911102","phase":"PHASE2","title":"Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2019-03-11","conditions":"Lateral Canthal Lines","enrollment":63},{"nctId":"NCT04886167","phase":"PHASE1, PHASE2","title":"Dysport Dose-Ranging Treatment of Platysmal Bands","status":"UNKNOWN","sponsor":"Clinical Testing of Beverly Hills","startDate":"2021-05-30","conditions":"Platysma Bands","enrollment":30},{"nctId":"NCT03321097","phase":"NA","title":"Condensed and Distributed Robotic Therapy in Spastic Stroke Post Botulinum Toxin Injection","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-10-01","conditions":"Stroke, Hemiplegia, Spastic","enrollment":36},{"nctId":"NCT00234546","phase":"PHASE4","title":"Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity","status":"COMPLETED","sponsor":"Ipsen","startDate":"2003-02","conditions":"Muscle Spasticity, Cerebrovascular Accident","enrollment":162},{"nctId":"NCT01189760","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-01","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":917},{"nctId":"NCT01797081","phase":"PHASE3","title":"BOTOX® in the Treatment of Crow's Feet Lines in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01-31","conditions":"Lateral Canthus Rhytides, Crow's Feet Lines","enrollment":300},{"nctId":"NCT01797094","phase":"PHASE3","title":"BOTOX® in the Treatment of Upper Facial Lines in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-02","conditions":"Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":101},{"nctId":"NCT01224015","phase":"PHASE3","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":684},{"nctId":"NCT01489904","phase":"PHASE2, PHASE3","title":"Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy","status":"UNKNOWN","sponsor":"Hospital Vall d'Hebron","startDate":"2011-11","conditions":"Sialorrhea, Cerebral Palsy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BOTOX®","BOTOX® Cosmetic","onabotulinumtoxinA"],"phase":"phase_3","status":"active","brandName":"onabotulinumtoxinA 24 U","genericName":"onabotulinumtoxinA 24 U","companyName":"Allergan","companyId":"allergan","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}